Results 311 to 320 of about 17,952,540 (402)

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

open access: yesMolecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang   +3 more
wiley   +1 more source

Well-being Tests of Between-Subjects Effects Reference Group - Target Group.

open access: green
L. C. Martijn (22794227)   +3 more
openalex   +1 more source

Home - About - Disclaimer - Privacy